Antibiotics Citations

1. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. Jan 6 2005;433(7021):73-77.
2. Mineur YS, Picciotto MR, Sanacora G. Antidepressant-Like Effects of Ceftriaxone in Male C57BL/6J Mice. Biol Psychiatry. Jan 15 2007;61(2):250-252.
3. Pickles HG, Simmonds M. Antagonism by penicillin of γ-aminobutyric acid depolarizations at presynaptic sites in rat olfactory cortex and cuneate nucleus in vitro. Neuropharmacology. 1980;19(1):35-38.
4. Kim DJ, King JA, Zuccarelli L, et al. Clavulanic acid: a competitive inhibitor of beta-lactamases with novel anxiolytic-like activity and minimal side effects. Pharmacol Biochem Behav. Aug 2009;93(2):112-120.
5. Kost GC, Selvaraj S, Lee YB, Kim DJ, Ahn CH, Singh BB. Clavulanic acid increases dopamine release in neuronal cells through a mechanism involving enhanced vesicle trafficking. Neurosci Lett. Oct 24 2011;504(2):170-175.
6. Palucha A, Tatarczynska E, Branski P, et al. Group III mGlu receptor agonists produce anxiolytic- and antidepressant-like effects after central administration in rats. Neuropharmacology. Feb 2004;46(2):151-159.
7. Zhou J, Neale JH, Pomper MG, Kozikowski AP. NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat Rev Drug Discov. Dec 2005;4(12):1015-1026.
8. Semenkov Yu P, Makarov EM, Makhno VI, Kirillov SV. Kinetic aspects of tetracycline action on the acceptor (A) site of Escherichia coli ribosomes. FEBS letters. Jul 19 1982;144(1):125-129.
9. Paribello C, Tao L, Folino A, et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC neurology. 2010;10:91.
10. Siller SS, Broadie K. Neural circuit architecture defects in a Drosophila model of Fragile X syndrome are alleviated by minocycline treatment and genetic removal of matrix metalloproteinase. Disease models & mechanisms. Sep-Oct 2011;4(5):673-685.
11. Agrawal SM, Lau L, Yong VW. MMPs in the central nervous system: where the good guys go bad. Seminars in cell & developmental biology. Feb 2008;19(1):42-51.
12. Ethell IM, Ethell DW. Matrix metalloproteinases in brain development and remodeling: synaptic functions and targets. Journal of neuroscience research. Oct 2007;85(13):2813-2823.
13. Levkovitz Y, Mendlovich S, Riwkes S, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. The Journal of clinical psychiatry. Feb 2010;71(2):138-149.
14. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clinical microbiology reviews. 1995;8(1):131-145.
15. Tedla Y, Shibre T, Ali O, et al. Serum antibodies to Toxoplasma gondii and Herpesvidae family viruses in individuals with schizophrenia and bipolar disorder: a case-control study. Ethiopian medical journal. 2011;49(3):211.
16. Winter C, Reutiman TJ, Folsom TD, et al. Dopamine and serotonin levels following prenatal viral infection in mouse—implications for psychiatric disorders such as schizophrenia and autism. European Neuropsychopharmacology. 2008;18(10):712-716.
17. Zink MC, Uhrlaub J, DeWitt J, et al. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA : the journal of the American Medical Association. Apr 27 2005;293(16):2003-2011.
18. Dutta K, Basu A. Use of minocycline in viral infections. The Indian journal of medical research. May 2011;133(5):467-470.
19. Mazzei T, Mini E, Novelli A, Periti P. Chemistry and mode of action of macrolides. Journal of Antimicrobial Chemotherapy. 1993;31(suppl C):1-9.
20. Jacobs MR, Johnson CE. Macrolide resistance: an increasing concern for treatment failure in children. Pediatr Infect Dis J. Aug 2003;22(8 Suppl):S131-138.
21. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman’s pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.
22. Richter SS, Heilmann KP, Beekmann SE, et al. Macrolide-resistant Streptococcus pyogenes in the United States, 2002–2003. Clinical infectious diseases. 2005;41(5):599-608.
23. Guchev I, Klochkov O, Ivanitsa G, IuA P, Shturmina S, Rosman S. Efficacy and safety of azithromycin prophylaxis of respiratory tract infections in military community. Antibiotiki i khimioterapiia= Antibiotics and chemoterapy [sic]/Ministerstvo meditsinskoi i mikrobiologicheskoi promyshlennosti SSSR. 2003;49(8-9):34-35, 37-42.
24. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. Eur J Clin Pharmacol. Nov 22 2011.
25. Murphy BS, Sundareshan V, Cory TJ, Hayes D, Anstead MI, Feola DJ. Azithromycin alters macrophage phenotype. Journal of Antimicrobial Chemotherapy. 2008;61(3):554-560.
26. Morikawa K, Torii I, Morikawa S. Modulation of IgD and CD20 by ligation of CD5 on tonsillar B cells. Scandinavian journal of immunology. 2002;55(1):44-52.
27. Liadaki K, Petinaki E, Skoulakis C, et al. Toll-like receptor 4 gene (TLR4), but not TLR2, polymorphisms modify the risk of tonsillar disease due to Streptococcus pyogenes and Haemophilus influenzae. Clin Vaccine Immunol. Feb 2011;18(2):217-222.
28. Loof TG, Goldmann O, Medina E. Immune recognition of Streptococcus pyogenes by dendritic cells. Infection and immunity. Jun 2008;76(6):2785-2792.
29. Banks WA, Kastin AJ, Broadwell RD. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation. Jul-Aug 1995;2(4):241-248.
30. Snider LA, Lougee L, Slattery M, Grant P, Swedo SE. Antibiotic prophylaxis with azithromycin or penicillin for childhood-onset neuropsychiatric disorders. Biological psychiatry. 2005;57(7):788-792.
31. Toufexis MD, DeOleo C, Elia J, Murphy TK. A Link Between Perianal Strep and Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infection (PANDAS). The Journal of Neuropsychiatry and Clinical Neurosciences. in press.
32. Ayoub EM, Wannamaker LW. Streptococcal antibody titers in Sydenham’s chorea. Pediatrics. 1966;38(6):946-956.
33. Murphy ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Archives of pediatrics & adolescent medicine. 2002;156(4):356.
34. Storch EA, Murphy TK, Geffken GR, et al. Cognitive-behavioral therapy for PANDAS-related obsessive-compulsive disorder: findings from a preliminary waitlist controlled open trial. Journal of the American Academy of Child & Adolescent Psychiatry. 2006;45(10):1171-1178.
35. Murphy TK, Storch EA, Strawser MS. Selective Serotonin Reuptake Inhibitor Induced Behavioral Activation in the PANDAS Subtype. Primary psychiatry. 2006;13(8):87-89.